Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate

뉴스 본문을 불러오고 있어요.

Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate | 웨이프 WAPE

Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate

기사 요약

관련 종목

댓글 —